262 related articles for article (PubMed ID: 25860442)
1. Bone marrow stromal antigen 2 (BST-2) DNA is demethylated in breast tumors and breast cancer cells.
Mahauad-Fernandez WD; Borcherding NC; Zhang W; Okeoma CM
PLoS One; 2015; 10(4):e0123931. PubMed ID: 25860442
[TBL] [Abstract][Full Text] [Related]
2. Bone marrow stromal antigen 2 expressed in cancer cells promotes mammary tumor growth and metastasis.
Mahauad-Fernandez WD; DeMali KA; Olivier AK; Okeoma CM
Breast Cancer Res; 2014 Dec; 16(6):493. PubMed ID: 25499888
[TBL] [Abstract][Full Text] [Related]
3. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
Gupta A; Godwin AK; Vanderveer L; Lu A; Liu J
Cancer Res; 2003 Feb; 63(3):664-73. PubMed ID: 12566312
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic regulation of cancer stem cell genes in triple-negative breast cancer.
Kagara N; Huynh KT; Kuo C; Okano H; Sim MS; Elashoff D; Chong K; Giuliano AE; Hoon DS
Am J Pathol; 2012 Jul; 181(1):257-67. PubMed ID: 22626806
[TBL] [Abstract][Full Text] [Related]
5. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
6. CpG promoter methylation of the ALKBH3 alkylation repair gene in breast cancer.
Stefansson OA; Hermanowicz S; van der Horst J; Hilmarsdottir H; Staszczak Z; Jonasson JG; Tryggvadottir L; Gudjonsson T; Sigurdsson S
BMC Cancer; 2017 Jul; 17(1):469. PubMed ID: 28679371
[TBL] [Abstract][Full Text] [Related]
7. EFEMP1 as a novel DNA methylation marker for prostate cancer: array-based DNA methylation and expression profiling.
Kim YJ; Yoon HY; Kim SK; Kim YW; Kim EJ; Kim IY; Kim WJ
Clin Cancer Res; 2011 Jul; 17(13):4523-30. PubMed ID: 21571867
[TBL] [Abstract][Full Text] [Related]
8. Exploring breast carcinogenesis through integrative genomics and epigenomics analyses.
Minning C; Mokhtar NM; Abdullah N; Muhammad R; Emran NA; Ali SA; Harun R; Jamal R
Int J Oncol; 2014 Nov; 45(5):1959-68. PubMed ID: 25175708
[TBL] [Abstract][Full Text] [Related]
9. 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer.
Zöchbauer-Müller S; Fong KM; Maitra A; Lam S; Geradts J; Ashfaq R; Virmani AK; Milchgrub S; Gazdar AF; Minna JD
Cancer Res; 2001 May; 61(9):3581-5. PubMed ID: 11325823
[TBL] [Abstract][Full Text] [Related]
10. Factors affecting the persistence of drug-induced reprogramming of the cancer methylome.
Bell JS; Kagey JD; Barwick BG; Dwivedi B; McCabe MT; Kowalski J; Vertino PM
Epigenetics; 2016 Apr; 11(4):273-87. PubMed ID: 27082926
[TBL] [Abstract][Full Text] [Related]
11. Promoter methylation reduces C/EBPdelta (CEBPD) gene expression in the SUM-52PE human breast cancer cell line and in primary breast tumors.
Tang D; Sivko GS; DeWille JW
Breast Cancer Res Treat; 2006 Jan; 95(2):161-70. PubMed ID: 16322893
[TBL] [Abstract][Full Text] [Related]
12. Methylation status of the Ep-CAM promoter region in human breast cancer cell lines and breast cancer tissue.
Spizzo G; Gastl G; Obrist P; Fong D; Haun M; Grünewald K; Parson W; Eichmann C; Millinger S; Fiegl H; Margreiter R; Amberger A
Cancer Lett; 2007 Feb; 246(1-2):253-61. PubMed ID: 16624485
[TBL] [Abstract][Full Text] [Related]
13. A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies.
Shames DS; Girard L; Gao B; Sato M; Lewis CM; Shivapurkar N; Jiang A; Perou CM; Kim YH; Pollack JR; Fong KM; Lam CL; Wong M; Shyr Y; Nanda R; Olopade OI; Gerald W; Euhus DM; Shay JW; Gazdar AF; Minna JD
PLoS Med; 2006 Dec; 3(12):e486. PubMed ID: 17194187
[TBL] [Abstract][Full Text] [Related]
14. HLJ1 (DNAJB4) Gene Is a Novel Biomarker Candidate in Breast Cancer.
Acun T; Doberstein N; Habermann JK; Gemoll T; Thorns C; Oztas E; Ried T
OMICS; 2017 May; 21(5):257-265. PubMed ID: 28481734
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation mediated silencing of microRNA-874 is a promising diagnosis and prognostic marker in breast cancer.
Zhang L; Yan DL; Yang F; Wang DD; Chen X; Wu JZ; Tang JH; Xia WJ
Oncotarget; 2017 Jul; 8(28):45496-45505. PubMed ID: 28525377
[TBL] [Abstract][Full Text] [Related]
16. Methylation of specific CpG sites in the P2 promoter of parathyroid hormone-related protein determines the invasive potential of breast cancer cell lines.
Tost J; Hamzaoui H; Busato F; Neyret A; Mourah S; Dupont JM; Bouizar Z
Epigenetics; 2011 Aug; 6(8):1035-46. PubMed ID: 21775817
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic up-regulation of leukemia inhibitory factor (LIF) gene during the progression to breast cancer.
Shin JE; Park SH; Jang YK
Mol Cells; 2011 Feb; 31(2):181-9. PubMed ID: 21191816
[TBL] [Abstract][Full Text] [Related]
18. Frequent epigenetic inactivation of the receptor tyrosine kinase EphA5 by promoter methylation in human breast cancer.
Fu DY; Wang ZM; Wang BL; Chen L; Yang WT; Shen ZZ; Huang W; Shao ZM
Hum Pathol; 2010 Jan; 41(1):48-58. PubMed ID: 19733895
[TBL] [Abstract][Full Text] [Related]
19. [Study of the CpG methylation status of ER alpha gene in estrogen receptor alpha-negative breast cancer cell lines and the role of hydralazine demethylation].
Tang B; Jiang J
Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):283-7. PubMed ID: 16181550
[TBL] [Abstract][Full Text] [Related]
20. Promoter methylation assay of SASH1 gene in breast cancer.
Sheyu L; Hui L; Junyu Z; Jiawei X; Honglian W; Qing S; Hengwei Z; Xuhui G; Qinghe X; Lin H
J BUON; 2013; 18(4):891-8. PubMed ID: 24344014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
